Vertex Pharma up 2% after hours on Q2 beat, guidance raise

Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 results ($M): Revenues: 941.3 (+25.1%); product sales: 940.4 (+25.4%).

Key product sales: Symdeko/Symkevi: 362 (+94.6%); Orkambi: 316 (+69.9%); Kalydeco: 262 (+3.6%).

Net income: 267.4 (+28.9%); non-GAAP net income: 327.3 (+34.1%); EPS: 1.03 (+28.8%) non-GAAP EPS: 1.26 (+34.0%).

2019 guidance: Product sales: $3.60B – 3.70B from $3.45B – 3.55B.

Shares up 2% after hours.

Previously: Vertex Pharmaceuticals EPS beats by $0.19, beats on revenue(July 31)

https://seekingalpha.com/news/3484652-vertex-pharma-2-percent-hours-q2-beat-guidance-raise